Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH002 in Combination with YH001 in Advanced Solid Tumors
NCT05169697Phase 1Completed
- Sponsor
- Eucure Biopharma
- Start
- Feb 2022
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of YH002 in solid tumor (advanced stage), sponsored by Eucure Biopharma. Primary endpoints: Maximum Tolerated Dose and Recommended Phase II Dose. Started Feb 2022; status: completed.
02
Drugs
YH002
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05169697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05169697.